一图看清恒瑞医药研发管线20220917

一图看清恒瑞医药研发管线 华创证券医药团队 2022-09-17 恒瑞已上市创新药适应症扩展进度 NDA 联A(5(x期) VEGFR 联A(TACE+联单) FNBRCA1ET的MUHER2E E(S4R-1791±(化/7) HIR1,HER2,HER4 联台(2HR-A1311) GARAA 联8(R27) PD-1REUIBNEMHAINSCLC) 饿8TPDL1N达ROEINE PARP (2t-2H%-B) ER比得) 有BRCA12E的HER2MR 合(SHR-A1811) 血TPO-R imCOK41G 联合(RFOLHNOX) 合(HRSIEOT) EHREHER2DMRXR HRE件、HER2用件R8 HRIEIS HRCHHER2uRRSLMA 9OLT-2(%4-2=) WEAR 恒瑞在研管线更新 广E (B) SHR-1316. PO-L1 BR(SHR-A1B11)BtA(SHR-0068) 合(SHR-1802) e(单-XELOX 88(7) (含+R) E/联合(R27) SHR:1701PD-L1/TGF-β单 检(8P102) VEGTR,FOFR,(U单多$ E(%(2.理+27) 联(+85单) +3 E:(:(t+SHR-1802) E合(SHR·1701) PD-LE (YY-20394) SHK1459BIx单的 r-2039 PI3X8 E:6(SHR1459) FAMI(62) F±(V-20394) 单的 SHR-1501IL-15 SHR-1702 SHR-468 SHR-41811HER2ADC E会(R得(单) 单药 HER2性不可解性理 HER2电的电任购HER2第YAH小EES S4R-1802 SHR-1916 L4G3 联合(R月) HISSUT SHR-61904单药 SHR-61912 HRS-3738 HRS2350HRS2543 单药 SHR-1901 SHR-42009单的 MRENIS SHR-2002HRS1167 HR54642 RRHITDPP-V SGLT2/=甲 聚台(二甲) (5+8池二)4 MB表/G(P-1韩范(85) MRS531 HRX37012±/N-dd0 SHR-114R-174 单药 单 SHR4640URAT1 zoccusJACI SIR-1819 8S185 SHR-1209CS9 心血 SHR22E5 SHR-204 SHR-1518 SHRa0eCY951单药 HRS8950Tut-a HRS5061Rzn SHR2150HRS5685 单药（美86数格话1型(HIV-1) HRS8427 SHRS554MOR HRS4800 SHR34107 HRSSIDT 单药 欧骨[SHR3410) 单✁ EA(SHR8554) SOLI-SHS单药 SHR-1506 SHR8028 SHRG5C8AW 单药 SHR-2010 SHR-1222SOST GrRI单 HR23013单药 SIR-17DT HBS-2261HRS8179 a-brs 恒瑞海外在研管线更新 INDNDA PO-1要国线卫大(售中国) F8瑞能BE/SHR3680 HER1,HER2.HER4 AR PARP联合(同比持边) ✁T)能(nHSPC) Ee/ADT) SHR-A1811 HER2-AGC 单书高风亚大(2于四)实体室 SHR1701 SHR-A1904 5-9±/11-0d单西 单药 SHR-2002单6 单药 开际多中心 IN5068HR17031 120-x 胰含低/GLP-1 单药 单药高风中国 SHRORU2JAK1单6 单药 RBeR RS1805 加除大,中国 OLEL-SHS 其他 SHR-1707单剪 SHR-1905 /单奶RM / 华创新药 数提来量：复财医药202中校：华2注养